| PTSGX | VIGAX | PTSGX / VIGAX | |
| Total Expense Ratio | 1.16 | 0.05 | 2,320% |
| Annual Report Gross Expense Ratio | 1.20 | 0.05 | 2,400% |
| Fund Existence | 26 years | 26 years | - |
| Gain YTD | -1.049 | 4.770 | -22% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 2500 | 3000 | 83% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.99B | 379B | 1% |
| Annual Yield % from dividends | 0.00 | 0.39 | - |
| Returns for 1 year | -4.37 | 12.36 | -35% |
| Returns for 3 years | 51.95 | 75.40 | 69% |
| Returns for 5 years | -11.41 | 72.79 | -16% |
| Returns for 10 years | 14.64 | 359.07 | 4% |
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BST | 46.26 | 0.59 | +1.29% |
| BlackRock Science and Technology Trust | |||
| JULB | 27.67 | 0.15 | +0.54% |
| Aptus July Buffer ETF | |||
| DYLD | 22.26 | N/A | -0.02% |
| LeaderShares® Dynamic Yield ETF | |||
| FDEV | 37.15 | -0.31 | -0.83% |
| Fidelity International Multifactor ETF | |||
| THNR | 25.40 | -0.47 | -1.81% |
| Amplify Weight Loss Drug & Treatment ETF | |||